Androgenetic alopecia in woman treated with botulinum toxin
- pdf |
- DOI: https://doi.org/10.15562/ism.v12i3.1205 |
- Published: 2021-12-30
Open Access & Peer Reviewed
Multidisciplinary Journal of Science and
Medical Research
Multidisciplinary Journal of Science and
Medical Research
Abstract
Background: Androgenetic alopecia (AGA) is the most common type of alopecia. AGA in women is called Female Pattern Hair Loss (FHPL). FHPL occurs in 50% of adolescence women.
Case Description: A 29-year-old woman presented with hair thinning on the top of her head in the last 3 years. Dermatological status in the parietal region showed a diffuse and ill-define patch of alopecia, and hair thinning was found along the midline of the scalp. The hair pull test in frontal, temporal, and parietal regions was negative. The Severity of Alopecia Tool (SALT) score is 10, and patient belonged to stage 2 according to The Sinclair Scale. Dermoscopy examination revealed scattered white dots over the vertex of the scalp with various hair diameters. Miniaturized hair and vellus hair were found in several areas. The ratio of terminal to vellus hair was 20:6 or 3:1. Injection of 100-unit botulinum toxin in the alopecia area was done every 3 months. After 1 month of treatment, the hair thinning was reduced.
Conclusion: Appropriate treatment will affect the prognosis of AGA patients. Appropriate treatment that based on the pathophysiology of the disease and the patient's genetics will provide a good therapeutic response.
References
- Mysore V, Parthasaradhi A, Matte P. Expert consensus on the management of androgenetic alopecia in India. Indian J trichology. 2019;11(3):101-106.
- Anonim. Buku register kunjungan sub divisi Kosmetik Medik Poliklinik Kulit dan Kelamin Rumah Sakit Umum Pusat Sanglah. Denpasar; 2018-2021.
- Sinclair R, Torkamani N, Jones L. Androgenetic alopecia: new insights into the pathogenesis and mechanism of hair loss. F1000Research. 2017;4(5):80-9.
- Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectiveness and safety of botulinum toxin type a in the treatment of androgenetic alopecia. BioMed Research International. 2020:1–7.
- Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: An update. Indian J Dermatol Venereol Leprol. 2018;79(5):613-25.
- Robert S. English Jr. A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. Medical Hypotheses. 2017;111(2018):73-81.
- Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women's Dermatology. 2018;4(4):203-211.
- Peytavi UB, Kanti V. Androgenic Alopecia. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K, editors. Fitzpatrick’s Dermatology in General Medicine. 9th ed. New York: McGraw-Hill; 2019. p.1495-1505.
- Kibar M, Aktan S, Bilgin M. Scalp dermatoscopic findings in androgenetic alopecia and their relations with disease severity. Ann Dermatol. 2014;26(4):478-84.
- Park J, Kim JI, Kim HU, Yun SK, Kim SJ. Trichoscopic findings of hair loss in korean. Ann Dermatol. 2015;27:539-50.
- Singh S, Neema S, Vasudevan B. A pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. J Cutan Aesthet Surg. 2017 Sep;10(3):163-7
- Rebora A, Guarrera M, Baldari M, Vechhio F. Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient. Arch Dermatol. 2018;141:1243-5.
How to Cite
Wijaya, H., & Winaya, K. K. (2021). Androgenetic alopecia in woman treated with botulinum toxin. Intisari Sains Medis, 12(3), 1050–1053. https://doi.org/10.15562/ism.v12i3.1205
